AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

Source: Benzinga ·

AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies cleared Klygefa for generalized myasthenia gravis and approved the Imfinzi combination regimen for muscle-invasive bladde

Read the full story at Benzinga

Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.

More from the world desk